📈 Live Market Tracking
Every NSE and BSE corporate filing, read and explained by AI within minutes — impact, key figures, short/long-term view and what to watch.
Live · AI analyzer runs every 5 min (07:00–23:55 IST)
Latest filing: 2026-09-23 11:32
232 analysed today
FollowTelegram
232
Today
149,633
All-time analysed
42,906
Positive
6,661
Negative
91,389
Neutral
8,609
Watch
📊 Last 7 days — analysed filings by sentiment
Note: These are AI-generated, educational summaries of public NSE
filings — grounded in each document, but not investment advice and possibly incomplete.
Verify against the original filing and consult a SEBI-registered adviser before acting.
21 announcements match the current filters (relevance ≥ 5).
Bombay HC Allows Provisional Release of 200 kg Ketamine Consignment on ₹72 Lakh Deposit
Supriya Lifescience received an order from the Hon'ble High Court of Bombay permitting the provisional release of a seized consignment of 200 kg of Ketamine Hydrochloride. The release is subject to a deposit of ₹72 lakh with the Assistant Commissioner of Customs, Export, within one week of the order dated September 22, 2026. However, the court clarified that authorities may continue adjudication and criminal proceedings under applicable laws, including Section 52A of the NDPS Act. The ₹72 lakh deposit is minor relative to the company's net worth of ₹1,198 crore and quarterly net profit of ₹49.68 crore (Dec 2025), but legal risks remain pending.
Confidence: HIGH
What changedThe High Court granted conditional provisional release of a detained export shipment upon payment of a ₹72 lakh deposit.
Why it mattersWhile the physical consignment can be retrieved, ongoing criminal and adjudication proceedings under the NDPS Act pose regulatory and reputational uncertainties.
Consignment quantity: 200 kgDeposit amount required: ₹72 lakhDeposit compliance timeline: within one week from the date of the orderShipping Bill date: June 2, 2026
📅 Short termThe company must deposit ₹72 lakh within one week to secure the goods, likely neutralizing immediate inventory lock-up but keeping legal overhang active.
📈 Long termStructural impact depends on the final outcome of the ongoing adjudication and criminal proceedings under the NDPS Act; any adverse finding could affect licensing or export operations.
⚠ Risk flags
- Active criminal proceedings and adjudication under the NDPS Act
- Potential regulatory penalties or restrictions on controlled substance exports
Key Highlights
Bombay HC allowed provisional release of 200 kg Ketamine Hydrochloride consignment under Shipping Bill No. 3780061.
Provisional release requires a deposit of ₹72 lakh with Customs within one week.
Court clarified that adjudication and criminal proceedings may continue as per law.
Authorities are permitted to follow procedures under Section 52A of the NDPS Act.
👀 What to Watch
Monitor upcoming filings for updates on the ongoing adjudication and any criminal proceedings under the NDPS Act.
Supriya Lifescience Sets Sep 4, 2026 Record Date for ₹1.00/Share Final Dividend
Supriya Lifescience Limited has fixed Friday, September 4, 2026, as the record date for determining shareholder entitlement to a final dividend of ₹1.00 per equity share (face value ₹2.00 each) for FY 2025-26. The dividend was recommended by the Board on May 27, 2026, and is subject to shareholder approval at the upcoming Annual General Meeting (AGM) on September 24, 2026. If approved, the dividend will be disbursed within 30 days of the AGM.
Confidence: HIGH
What changedFormal fixation of the record date and AGM date for FY 2025-26 final dividend distribution.
Why it mattersConfirms the timeline for cash distribution to shareholders following FY 2025-26 financial performance.
Final dividend per share: Re. 1.00/-Face value per share: Rs. 2/-Record date: 04-Sep-2026AGM date: 24-Sep-2026
📅 Short termShare price will trade ex-dividend around the record date; no major operational impact.
📈 Long termLimited; reflects routine capital return policy aligned with company earnings.
Key Highlights
Final dividend recommended at ₹1.00 per equity share of face value ₹2.00 each for FY 2025-26
Record date fixed as Friday, September 4, 2026
18th AGM scheduled for Thursday, September 24, 2026 at 3:00 p.m. IST via Video Conferencing
Dividend payment to be completed within 30 days of shareholder approval at the AGM
👀 What to Watch
Investors seeking dividend eligibility must hold shares in their demat accounts prior to the record date of September 4, 2026, and track AGM voting outcomes on September 24, 2026.
Q1 FY27 Revenue Up 31% YoY to Rs 190 Cr; EBITDA Margin Dips to 25% on Cost Headwinds
Supriya Lifescience reported Q1 FY27 revenue of Rs 190 crore, up 31% YoY, despite a Rs 35 crore sales deferment caused by localized water scarcity. EBITDA declined 8.1% YoY to Rs 47 crore with margins contracting to 25%, weighed down by Rs 10.5 crore in transient cost headwinds including a Maharashtra solar power policy change (Rs 8 crore impact) and elevated solvent costs. Net profit came in at Rs 24 crore against Rs 35 crore in Q1 FY26. Management reiterated its full-year guidance of delivering normalized EBITDA margins of 33%-35% and reaching Rs 1,000 crore revenue by FY27, backed by a planned Rs 200 crore Phase-1 capex at Patalganga.
Confidence: HIGH
What changedFiling of the Q1 FY27 earnings call transcript providing color on operational deferments, cost headwinds, and expansion roadmaps.
Why it mattersAssures investors that the Q1 margin drop to 25% was transient rather than structural, while keeping the multi-year Rs 1,000 crore revenue target intact.
Q1 FY27 Revenue: Rs. 190 croresDeferred Sales: Rs. 35 croresOne-off Cost Impact: Rs. 10.5 croresQ1 FY27 EBITDA Margin: 25%Patalganga Phase-1 Capex: Rs. 200 croresPhase-1 Capex vs Net Worth: ~16.7%
📅 Short termOperating performance should rebound in subsequent quarters as monsoon rains ease water shortages and maintenance is done in phases without full shutdowns.
📈 Long termBackward integration (72% integrated) and moving into high-barrier regulated markets and finished formulations support the trajectory towards the Rs 1,000 crore revenue goal.
⚠ Risk flags
- Regional utility dependencies (water shortages at Lote MIDC)
- Regulatory shifts in state power/solar tariffs affecting energy costs
- High geographical concentration in exports (81% of revenues)
Key Highlights
Q1 FY27 revenue rose 31% YoY to Rs 190 crore, impacted by Rs 35 crore in deferred sales due to water shortages
EBITDA decreased 8.1% YoY to Rs 47 crore with EBITDA margin at 25% due to Rs 10.5 crore in temporary cost pressures
Net profit dropped to Rs 24 crore compared to Rs 35 crore in Q1 FY26
Management reaffirmed midterm revenue target of Rs 1,000 crore by FY27 and EBITDA margin band of 33%-35%
Earmarked ~Rs 200 crore for Phase-1 Patalganga capex (~16.7% of Rs 1,198 crore Net Worth), funded partly via Rs 150 crore in cash reserves
👀 What to Watch
Track the recovery of the Rs 35 crore deferred sales and verify whether EBITDA margins recover toward the guided 33%-35% band in Q2 FY27 results.
31% Revenue Growth in Q1 FY27 but PAT Drops 31% as Margins Contract
Supriya Lifescience reported a strong 30.8% YoY revenue growth to ₹189.75 Cr for Q1 FY27, driven by expansion in Asia and the Vitamin segment. However, profitability faced significant pressure as EBITDA margins contracted sharply from 35.6% to 25.0%, leading to an 8.2% YoY decline in EBITDA. Consequently, PAT fell 30.9% YoY to ₹24.04 Cr. While the top-line growth is robust, the substantial margin compression reflects potential pricing headwinds or higher operational costs during its transition into finished dosages.
Confidence: HIGH
What changedThe company achieved significant volume-led revenue growth but experienced a sharp decline in profitability margins and absolute net profit.
Why it mattersThe margin contraction is a concern for a company that previously guided for 33-35% margins; the shift toward finished dosages and new markets is currently impacting the bottom line.
Revenue (Q1 FY27): ₹189.75 CrEBITDA Margin: 25.0%PAT Margin: 12.7%Export Revenue Share: 81%Total Reactor Capacity: 932 KLPDQuarterly Revenue vs Net Worth: 15.8%
📅 Short termThe stock may face pressure in the short term due to the significant miss on margins and the YoY decline in PAT despite higher sales.
📈 Long termLong-term value depends on the successful commercialization of the finished dosage business and whether the new R&D-led product launches can restore margins to the 30%+ range.
⚠ Risk flags
- Sharp margin contraction (1,060 bps)
- High export dependency (81%)
- Declining capacity utilization (70% vs 74% in FY26)
Key Highlights
Revenue increased 30.8% YoY to ₹189.75 Cr from ₹145.07 Cr in Q1 FY26.
EBITDA margin compressed by 1,060 basis points to 25.0% compared to 35.6% in the previous year.
Profit After Tax (PAT) declined 30.9% YoY to ₹24.04 Cr from ₹34.79 Cr.
Asia became the largest market contributing 39% of revenue, up from 32% YoY.
Capacity utilization stood at 70% for the quarter, down from 74% in FY26.
👀 What to Watch
Investors should monitor the stabilization of margins as the company scales its new finished dosage facility at Ambernath and tracks the ramp-up of the ADHD and Cardiovascular product pipelines.
Supriya Lifescience Q1 PAT Drops 31% YoY to ₹24.04 Cr Despite 31% Revenue Growth
Supriya Lifescience reported a weak Q1 FY27 with Net Profit (PAT) declining 30.9% YoY to ₹24.04 cr, despite a 30.8% increase in Revenue from Operations to ₹189.75 cr. The profitability was severely impacted by a 149.9% surge in raw material costs, which rose to ₹109.40 cr from ₹43.78 cr in the previous year. Sequentially, the performance was even more subdued, with revenue and PAT falling 31.4% and 67.6% respectively compared to Q4 FY26. A specific note mentions that export goods detained by Customs were recognized as sales, which warrants attention regarding revenue certainty.
Confidence: HIGH
What changedThe company experienced a significant margin squeeze in Q1 FY27, where high input costs and increased operating expenses offset healthy top-line growth.
Why it mattersThe sharp decline in profitability and sequential drop in revenue suggests operational headwinds or a shift in product mix that is currently less lucrative, challenging the company's high ROCE profile.
Revenue from Operations (Q1 FY27): ₹189.75 crNet Profit (PAT) (Q1 FY27): ₹24.04 crCost of Materials Consumed: ₹109.40 crYoY Revenue Growth: 30.8%QoQ PAT Growth: -67.6%Q1 Revenue vs Net Worth: 15.8%
📅 Short termThe stock may face downward pressure in the short term due to the significant earnings miss and sharp sequential decline in profitability.
📈 Long termThe long-term outlook depends on the successful transition to regulated markets and the scaling of the finished formulation business to restore margins to historical levels.
⚠ Risk flags
- Sharp increase in raw material costs (up 150% YoY)
- Significant sequential decline in revenue and profit
- Revenue recognition for goods detained by Customs
- High dependency on exports (81% of revenue) making it sensitive to global logistics and regulations
Key Highlights
Revenue from operations grew 30.8% YoY to ₹189.75 cr, but fell 31.4% sequentially from ₹276.53 cr.
Net Profit (PAT) contracted 30.9% YoY to ₹24.04 cr, down from ₹34.79 cr in Q1 FY26.
Cost of materials consumed spiked to ₹109.40 cr, representing 57.6% of revenue compared to 30.2% in the year-ago quarter.
Total expenses increased by 51.1% YoY to ₹151.60 cr, significantly outpacing revenue growth.
Basic EPS for the quarter stood at ₹2.99, down from ₹4.32 in Q1 FY26 and ₹9.22 in Q4 FY26.
👀 What to Watch
Investors should monitor the stabilization of raw material costs and management's ability to pass on these costs to maintain their midterm margin guidance of 33-35%. The resolution of the Customs detention issue mentioned in the notes is also a key monitorable for revenue realization.
30.8% Revenue Growth in Q1 FY27; EBITDA Margins Compress to 25% on Higher Costs
Supriya Lifescience reported a strong 30.8% YoY revenue growth to ₹189.75 Cr for Q1 FY27, driven by robust demand in Asia and Europe. However, profitability faced significant pressure as EBITDA fell 8.2% YoY to ₹47.46 Cr, with margins contracting by 1,063 bps to 25.0% due to a 77.5% surge in Cost of Goods Sold (COGS). Consequently, PAT declined 30.9% YoY to ₹24.04 Cr. The company is aggressively pivoting towards Finished Dosages with 30 products in the R&D pipeline and has recently commissioned a new vitamin product block to support future growth.
Confidence: HIGH
What changedThe company has transitioned to a higher revenue base but is currently grappling with significantly higher input costs and operating expenses, leading to a sharp decline in net profit margins from 24.0% to 12.7% YoY.
Why it mattersThe shift toward Finished Dosages and backward integration (currently covering 72% of revenue) is critical for Supriya to regain its historical margin profile and reduce dependency on volatile API cycles.
Revenue Growth (YoY): 30.8%EBITDA Margin: 25.0%PAT (Q1 FY27): ₹24.04 CrExport Revenue Share: 81%COGS Increase (YoY): 77.5%R&D Pipeline (Dosages): 30 products
📅 Short termThe stock may face pressure due to the significant margin contraction and YoY PAT decline, despite the healthy top-line growth.
📈 Long termThe structural move into regulated markets and finished dosages, supported by a debt-free balance sheet and 25% ROCE, remains a positive long-term narrative if margins can be restored.
⚠ Risk flags
- Significant margin volatility
- High export dependency (81%)
- Sharp increase in raw material costs (COGS up 77.5%)
Key Highlights
Revenue from operations increased 30.8% YoY to ₹1,897.5 Mn, though it declined 31.4% on a sequential (QoQ) basis.
EBITDA margins dropped to 25.0% from 35.6% in the previous year's quarter, primarily due to a 77.5% increase in COGS.
Exports continue to dominate the business mix, contributing 81% of total revenue in Q1 FY27.
The Finished Dosage R&D division has 30 products under development across various forms including tablets, capsules, and injections.
The company maintains a healthy leverage profile with a Debt-to-Equity ratio of 0.00 as of the latest reporting.
👀 What to Watch
Investors should monitor the stabilization of EBITDA margins, which have deviated from the management's mid-term guidance of 33%-35%. Key triggers to watch include the commercialization timeline of the 30-product dosage pipeline and the capacity ramp-up at the newly commissioned vitamin block.
Supriya Lifescience Q1 Revenue up 31% YoY to ₹189.7 cr; PAT falls 31% on high input costs
Supriya Lifescience reported a 30.8% YoY increase in revenue from operations to ₹189.75 crore for Q1 FY27. However, Net Profit (PAT) declined by 30.9% YoY to ₹24.04 crore, primarily due to a sharp 149.9% surge in raw material costs, which rose to ₹109.40 crore. Sequentially, the performance was weak, with revenue dropping 31.4% from ₹276.53 crore in the preceding quarter. A specific note mentions that export materials detained by Customs were recognized as sales, which investors should monitor for potential reversals or delays.
Confidence: HIGH
What changedThe company experienced a significant margin squeeze in Q1 FY27, where robust top-line growth was offset by a disproportionate increase in input costs.
Why it mattersWhile the company is expanding its market reach, the current quarter shows vulnerability to raw material price volatility, impacting the bottom line and deviating from the midterm margin guidance of 33%-35%.
Revenue (Q1 FY27): ₹189.75 crNet Profit (Q1 FY27): ₹24.04 crYoY Revenue Growth: 30.8%YoY PAT Growth: -30.9%Cost of Materials Consumed: ₹109.40 crQoQ Revenue Growth: -31.4%
📅 Short termThe stock may face pressure in the short term due to the significant PAT miss and the sharp sequential decline in revenue and profitability.
📈 Long termLong-term prospects depend on the company's ability to pass on higher input costs and successfully transition to higher-margin regulated markets and finished formulations.
⚠ Risk flags
- Sharp increase in raw material costs
- Significant sequential revenue volatility
- Operational risk regarding export shipments detained by Customs
Key Highlights
Revenue from operations increased 30.8% YoY to ₹189.75 crore from ₹145.07 crore.
Net Profit (PAT) fell 30.9% YoY to ₹24.04 crore compared to ₹34.79 crore in the year-ago period.
Cost of Materials Consumed surged to ₹109.40 crore, up from ₹43.78 crore in Q1 FY26.
Earnings Per Share (EPS) dropped to ₹2.99 from ₹4.32 YoY.
Total expenses rose 51% YoY to ₹151.60 crore, significantly outpacing revenue growth.
👀 What to Watch
Watch for management commentary regarding the sharp spike in raw material costs and the sequential revenue decline. Monitor the resolution of the Customs detention issue mentioned in the notes, as it impacts the timing of cash flows despite being recognized as revenue.
GM Sales & Marketing in judicial custody until July 17, 2026, under NDPS Act investigation
Supriya Lifescience has disclosed that its General Manager of Sales & Marketing, Mr. Sreekant Sreedharan, is in judicial custody until July 17, 2026. The investigation, initiated by the Special Investigation and Intelligence branch of the Customs Department, involves an alleged procedural lapse in a single export transaction under the Narcotic Drugs and Psychotropic Substances (NDPS) Act, 1985. While the company maintains that this will not have a material impact on operations or financials, the involvement of narcotics-related regulations is a sensitive matter for a pharma exporter. The company is currently seeking legal advice and monitoring the situation closely.
Confidence: HIGH
What changedA senior management official (GM Sales & Marketing) has been detained by customs authorities regarding a legal violation related to an export transaction.
Why it mattersFor a pharmaceutical company with high export dependency (81%), any investigation under the NDPS Act carries significant reputational and regulatory risk, even if the company currently deems it non-material.
Custody end date: July 17, 2026Export dependency: 81%Event occurrence date: July 3, 2026Net worth: Rs 1198 Cr
📅 Short termThe stock may experience volatility or negative sentiment in the coming days as the market assesses the severity of the NDPS-related investigation.
📈 Long termThe long-term impact is likely limited if the issue is confirmed as a one-off procedural lapse; however, any systemic compliance failure could lead to stricter regulatory oversight.
⚠ Risk flags
- Regulatory risk (NDPS Act)
- Key personnel risk
- Reputational risk
Key Highlights
Judicial custody granted by CMM court for the GM Sales & Marketing until July 17, 2026
Investigation initiated on July 3, 2026, by the Customs Department's Special Investigation and Intelligence branch
Proceedings initiated under the Narcotic Drugs and Psychotropic Substances (NDPS) Act, 1985
Matter pertains to an alleged procedural lapse for a single export transaction
Company reports 81% of revenue is dependent on exports, making regulatory compliance critical
👀 What to Watch
Investors should monitor for updates following the July 17, 2026, court date and watch for any further regulatory actions from the Customs Department that could affect export licenses.
Supriya Lifescience FY26 Revenue Up 19% to ₹828 Cr; Targets ₹1,000 Cr Milestone by FY27
Supriya Lifescience reported a resilient FY26 performance with revenue growing 18.9% YoY to ₹828 crore, hitting its guided growth target. The company achieved its highest-ever annual EBITDA of ₹294 crore with a robust margin of 35.5%, surpassing the guided range of 33-35%. A key regulatory milestone was reached with the USFDA issuing an EIR for the Lote facility with a VAI classification. Management has reiterated a revenue target of ₹1,000 crore by FY27, supported by new product launches in ADHD and anesthetic segments and the upcoming Patalganga expansion.
Key Highlights
Achieved record quarterly revenue of ₹277 crore in Q4 FY26, a 50% YoY increase.
Maintained strong EBITDA margins at 35.5% for both Q4 and the full year FY26.
Exports contributed 82% of FY26 revenue, with Europe alone accounting for a 40% share.
Announced ₹200 crore Phase 1 capex for Patalganga facility, with groundbreaking scheduled for FY27.
Backward integration reached 76%, strengthening cost efficiency and supporting sustainable growth.
👀 What to Watch
Investors should take confidence in the company's ability to meet growth guidance and maintain high margins. Key triggers to watch include the commercialization of contrast media products in H2 FY27 and the execution of the Patalganga expansion.
Supriya Lifescience Q4 Revenue Surges 50.2% YoY to ₹276.53 Cr; FY26 PAT at ₹209.12 Cr
Supriya Lifescience delivered a robust performance in Q4 FY26, with revenue growing 50.2% YoY to ₹276.53 crore and PAT increasing to ₹74.23 crore. For the full year FY26, revenue rose 18.9% to ₹827.87 crore, supported by a 74% capacity utilization rate. While EBITDA margins saw a slight compression from 37.4% to 35.5% for the full year, the anesthetic segment remained a dominant growth driver, contributing 54% of total revenue. The company is actively expanding through land acquisitions and the commissioning of five new manufacturing lines at its Ambernath formulation facility.
Key Highlights
Q4 FY26 revenue grew 50.2% YoY to ₹276.53 crore, while PAT increased to ₹74.23 crore.
Full-year FY26 PAT reached ₹209.12 crore with an EPS of ₹25.98.
Anesthetic segment contribution increased to 54% of total revenue in FY26 from 49% in FY25.
Export contribution remains strong at 82%, with Europe being the largest market at 40% of revenue.
Capacity utilization improved to 74% in FY26, up from 70% in the previous fiscal year.
👀 What to Watch
Investors should focus on the company's ability to maintain high margins while scaling its new Ambernath formulation facility and newly launched products in the cardiovascular and ADHD segments.
Supriya Lifescience Q4 FY26 Revenue Surges 50% YoY to INR 276.5 Cr; PAT Rises 47%
Supriya Lifescience reported a strong Q4 FY26 with revenue growing 50.2% YoY to INR 2,765.3 Mn, driven by robust export performance which accounts for 82% of total revenue. The company's EBITDA for the quarter rose 44.4% to INR 976.2 Mn, though margins slightly contracted by 141 bps YoY to 35.3%. Full-year FY26 performance was also positive, with PAT increasing 11.3% to INR 2,091.2 Mn and total revenue reaching INR 8,278.7 Mn. Key growth drivers include the scale-up of ADHD and Cardiovascular products, alongside the commercialization of Liquid Anesthesia.
Key Highlights
Q4 FY26 Revenue grew 50.2% YoY to INR 2,765.3 Mn; FY26 Revenue up 18.9% to INR 8,278.7 Mn
Q4 FY26 PAT increased 47.4% YoY to INR 742.3 Mn with an EPS of INR 9.22
Export revenue remains dominant at 82% for FY26, with Europe contributing 44% of Q4 revenue
Anesthetic therapy remains the largest segment, contributing 54% of FY26 revenue
Total reactor capacity stands at 932 KLPD across 5 manufacturing blocks
👀 What to Watch
Investors should note the strong revenue momentum and successful product diversification into ADHD and Cardiovascular segments. Monitor the stabilization of margins and the progress of the upcoming FY27 product pipeline.
Supriya Lifescience Q4 Profit Jumps 47% to ₹74.2 Cr; Recommends ₹1 Dividend
Supriya Lifescience reported a robust performance for Q4 FY26, with revenue from operations growing 50.2% year-on-year to ₹276.53 crore. Net profit for the quarter rose significantly by 47.3% to ₹74.23 crore compared to ₹50.38 crore in the same period last year. The Board has recommended a final dividend of ₹1 per share (50% of face value), reflecting confidence in the company's cash flow. For the full year FY26, the company achieved a total revenue of ₹827.88 crore and a net profit of ₹209.12 crore.
Key Highlights
Revenue from operations for Q4 FY26 stood at ₹276.53 crore, up from ₹184.11 crore in Q4 FY25.
Net profit for the quarter increased to ₹74.23 crore, representing a 47.3% YoY growth.
Recommended a final dividend of ₹1.00 per equity share of face value ₹2.00 (50% payout).
Full-year FY26 revenue reached ₹827.88 crore with a total comprehensive income of ₹209.02 crore.
Profit before tax for the quarter stood at ₹92.13 crore, showing strong operational efficiency.
👀 What to Watch
The company shows robust growth in both top-line and bottom-line figures along with a steady dividend payout. Investors should maintain a positive outlook while monitoring the sustainability of these margins in the upcoming quarters.
Supriya Lifescience Q4 FY26 Net Profit Jumps 47% YoY to 742.29 Million; ₹1 Dividend Declared
Supriya Lifescience Limited reported a robust performance for Q4 FY26, with revenue from operations rising to 2,765.28 million from 1,841.09 million in the previous year's corresponding quarter. Net profit for the quarter saw a significant increase of 47.3% YoY, reaching 742.29 million. For the full fiscal year 2026, the company achieved a total income of 8,393.62 million and a net profit of 2,091.20 million. Additionally, the board has recommended a final dividend of ₹1.00 per equity share (50% of face value).
Key Highlights
Revenue from operations grew by 50.2% YoY to 2,765.28 million in Q4 FY26.
Net profit for Q4 FY26 stood at 742.29 million, up from 503.82 million in Q4 FY25.
Full-year FY26 net profit reached 2,091.20 million on a total income of 8,393.62 million.
Recommended a final dividend of ₹1.00 per equity share of face value ₹2.00 each.
Total expenses for the quarter were managed at 1,878.77 million against a total income of 2,800.06 million.
👀 What to Watch
Investors should note the strong top-line and bottom-line growth, indicating improved operational efficiency and market demand. The stock remains a positive hold given the consistent dividend payout and healthy profit margins.
Supriya Lifescience Receives USFDA EIR with VAI Status for Lote Facility
Supriya Lifescience has successfully concluded its USFDA inspection for the manufacturing facility located at Lote, Maharashtra. The inspection, which took place from February 2 to February 6, 2026, initially resulted in a Form 483 with one minor observation. The company has now received the Establishment Inspection Report (EIR) with a 'Voluntary Action Indicated' (VAI) status, signifying successful completion. This regulatory clearance confirms the facility's compliance with cGMP standards and supports the company's export capabilities to the US market.
Key Highlights
USFDA inspection conducted at the Lote manufacturing facility from February 2 to February 6, 2026
Inspection concluded with only 1 minor observation issued via Form 483
Received Establishment Inspection Report (EIR) with 'Voluntary Action Indicated' (VAI) status
Successful completion confirms full compliance with current Good Manufacturing Practice (cGMP) requirements
👀 What to Watch
Investors should view this as a positive regulatory milestone that de-risks the company's US export business. The successful closure of the USFDA audit reinforces confidence in the company's quality control systems.
Supriya Lifescience Q3 FY26: Revenue Grows 11% to ₹206 Cr, Maintains 20% Growth Guidance
Supriya Lifescience reported a steady Q3 FY26 with revenue increasing 11% YoY to ₹206 crores and a PAT of ₹50 crores. The company maintained a strong EBITDA margin of 34.9%, supported by high-margin niche products and an 82% export contribution. Management reaffirmed its 20% annual revenue growth guidance and the ₹1,000 crore revenue milestone target for FY27. Key growth drivers include the launch of cardiovascular and ADHD products and the upcoming capitalization of the Ambernath facility in Q4 FY26.
Key Highlights
Q3 FY26 revenue rose 11% YoY to ₹206 crores with an EBITDA margin of 34.9% (₹72 crores).
Exports contributed 82% of total revenue, led by LatAm (24%) and North America (6%).
Ambernath facility is ready for capitalization in Q4 FY26, which is a key milestone for the CDMO segment.
Management maintains FY26 guidance of 20% revenue growth and 33-35% EBITDA margins.
Backward integration initiatives supported 74% of revenues, strengthening the overall cost structure.
👀 What to Watch
Investors should monitor the scale-up of new cardiovascular and ADHD products in Q4, which are expected to drive the guided 20% annual growth. The capitalization of the Ambernath facility remains a key trigger for the expansion of the CDMO business.
Supriya Lifescience Q3 FY26 Revenue Up 11.2% YoY to ₹206.4 Cr; PAT at ₹49.7 Cr
Supriya Lifescience reported a steady 11.2% YoY revenue growth for Q3 FY26, reaching ₹206.44 crore, driven by strong demand in the anesthetic segment and expansion in Latin American markets. While EBITDA grew by 9.3% to ₹72.08 crore, margins saw a slight contraction to 34.9% from 35.5% in the previous year. Net profit increased by 6.2% YoY to ₹49.68 crore, supported by a high export contribution of 82%. The company is preparing for the commercial launch of its Ambernath formulation facility in Q4 FY26 and has acquired land for future expansion.
Key Highlights
Revenue grew 11.2% YoY to ₹206.44 crore, while PAT increased 6.2% to ₹49.68 crore.
Anesthetic segment contribution rose to 54% of total revenues in 9M FY26 from 48% YoY.
Capacity utilization improved to 76% in 9M FY26, up from 70% in the previous fiscal year.
Geographic diversification improved with North America share doubling to 6% and LatAm rising to 24%.
Acquired three new land parcels and scheduled Ambernath facility launch for Q4 FY26.
👀 What to Watch
Investors should monitor the successful commissioning of the Ambernath facility in Q4 FY26 as a key growth catalyst. The stock remains attractive due to high margins and strong export presence, though margin stabilization should be watched.
Supriya Lifescience Q3 FY26 Revenue Up 11.2% YoY to ₹2,064 Mn; PAT Grows 6.2%
Supriya Lifescience reported a steady performance for Q3 FY26, with revenue from operations growing 11.2% YoY to ₹2,064.4 million. While EBITDA increased by 9.3% to ₹720.8 million, margins saw a slight compression of 61 bps to 34.9% due to higher employee and other expenses. The company continues to strengthen its backward integration, which now accounts for 74% of 9M FY26 revenue. Key growth drivers include the expansion into Liquid Anesthesia and the upcoming commissioning of the Ambernath FDF facility in H2 FY26.
Key Highlights
Revenue from operations grew 11.2% YoY to ₹2,064.4 Mn in Q3 FY26.
EBITDA stood at ₹720.8 Mn with a margin of 34.9%, while PAT grew 6.2% YoY to ₹496.8 Mn.
Anesthetics segment dominated the therapy mix, contributing 54% to 9M FY26 revenue.
Export markets remain strong, contributing 82% of total revenue in Q3 FY26.
Total reactor capacity reached 932 KLPD with the addition of the 335 KLPD Block E.
👀 What to Watch
Investors should monitor the ramp-up of the newly commissioned Block E and the upcoming Ambernath FDF facility for margin improvement. The company's strong backward integration and leadership in niche APIs provide a competitive moat.
Supriya Lifescience Appoints New Independent Directors and Reconstitutes Board Committees
Supriya Lifescience has strengthened its board by appointing two new Additional Independent Directors, Mr. Manish Panchal and Mr. Kothandaraman Hari, for five-year terms effective February 9, 2026. Mr. Hari brings significant capital markets expertise as a former Executive Vice President at the NSE, while Mr. Panchal offers over 32 years of experience in the chemical and pharma sectors. The company also re-appointed Dr. Neelam Yashpal Arora for a second five-year term as an Independent Woman Director. These appointments coincide with the approval of the unaudited financial results for the quarter ended December 31, 2025.
Key Highlights
Appointment of Mr. Kothandaraman Hari (former NSE EVP) as Additional Independent Director for a 5-year term.
Appointment of Mr. Manish Panchal (Business Leader with 32+ years experience) as Additional Independent Director for a 5-year term.
Re-appointment of Dr. Neelam Yashpal Arora as Independent Woman Director for a second term from 2026 to 2031.
Reconstitution of the Audit, Nomination and Remuneration, and Stakeholders’ Relationship Committees.
Board approval of unaudited financial results for the quarter and nine months ended December 31, 2025.
👀 What to Watch
Investors should view the addition of a capital markets veteran and a strategy expert to the board as a positive step for corporate governance. While the management changes are routine, shareholders should focus on the Q3 FY26 financial results to assess the company's current growth trajectory.
Supriya Lifescience Appoints Former NSE EVP to Board; Approves Q3 FY26 Results
Supriya Lifescience has approved its unaudited financial results for the quarter ended December 31, 2025, alongside significant board-level appointments. The company has inducted Mr. Kothandaraman Hari, a former Executive VP at the National Stock Exchange (NSE) with 28 years of experience, and Mr. Manish Panchal, a veteran in the pharma and chemical sectors, as Independent Directors. Additionally, Dr. Neelam Yashpal Arora was re-appointed for a second five-year term. These moves, including the reconstitution of key board committees, signal a strong push toward enhanced corporate governance and strategic oversight.
Key Highlights
Approved unaudited financial results for the quarter and nine months ended December 31, 2025.
Appointed Mr. Kothandaraman Hari, a capital markets veteran and former NSE Executive VP, as an Independent Director for 5 years.
Appointed Mr. Manish Panchal, with 32+ years of experience in Chemicals and Pharma, as an Additional Independent Director.
Re-appointed Dr. Neelam Yashpal Arora as Independent Woman Director for a second 5-year term effective March 2026.
Reconstituted the Audit, Nomination & Remuneration, and Stakeholders’ Relationship Committees with new independent leadership.
👀 What to Watch
The addition of a high-profile capital markets veteran from the NSE to the board is a positive indicator for corporate governance and institutional credibility. Investors should view these leadership changes as a strategic move to strengthen the company's market positioning and compliance framework.
Supriya Lifescience Appoints New Independent Directors and Approves Q3 FY26 Results
Supriya Lifescience's board met on February 09, 2026, to approve the unaudited financial results for the quarter ended December 31, 2025. The company announced the re-appointment of Dr. Neelam Yashpal Arora and the induction of two new independent directors, Mr. Manish Panchal and Mr. Kothandaraman Hari, for five-year terms. Mr. Hari brings significant capital markets expertise from his 28-year tenure at the National Stock Exchange (NSE). These appointments aim to strengthen corporate governance and strategic oversight as the company reconstitutes its key board committees.
Key Highlights
Approved unaudited financial results for the quarter and nine months ended December 31, 2025.
Appointed Mr. Kothandaraman Hari, former Executive VP at NSE, as an Additional Independent Director for a 5-year term.
Appointed Mr. Manish Panchal, a business leader with 32+ years of experience in Chemicals and Pharma, as an Additional Independent Director.
Re-appointed Dr. Neelam Yashpal Arora as Independent Woman Director for a second 5-year term starting March 2026.
Reconstituted the Audit, Nomination & Remuneration, and Stakeholders’ Relationship Committees with new independent members.
👀 What to Watch
Investors should review the detailed Q3 FY26 financial statements to assess the company's growth trajectory. The addition of high-caliber professionals from the NSE and the pharma industry to the board is a positive sign for governance and strategic planning.
